drugset
drugset / Trial / NCT03161366

Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine

NCT03161366 ↗

Phase 3 Completed 500 enrolled Epicentre Medecins Sans Frontieres, Netherlands · collab
NaSingle-groupOpen-labelPrevention

Summary

Interventional, single arm, open-label, non-randomized, phase IIIb study to accumulate additional data on safety and effectiveness of one dose of rVSVΔG-ZEBOV-GP against Ebola virus disease.

Timeline

Start
2018-05-28
Primary completion
2018-07-14
Completion
2018-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject rVSVΔG-ZEBOV-GP Vaccine 2e+07 unknown —

Indications

Ebola hemorrhagic fever